Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Condition:   Metastatic Hormone-Sensitive Prostate Cancer Interventions:   Drug: docetaxel 50mg/m2;   Drug: docetaxel 75mg/m2 Sponsor:   Peng Wang Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials